Positive Clinical Data in Pancreatic Cancer and SCLC, including Single-Agent Activity from Onvansertib Monotherapy
“We are excited that the data released from these trials, in two challenging cancers with low survival rates, expands the opportunity for onvansertib beyond our lead program in RAS-mutated mCRC,” said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. “In pancreatic cancer, the strength of the data provides a clear rationale for a first-line trial using onvansertib in combination with standard of care, which we believe provides the greatest opportunity for a positive impact on patients. In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting.”
Share:
More News
“The positive CHMP recommendation for the Itovebi-based regimen represents a significant step towards providing people in the EU with PIK3CA-mutated, ER-positive advanced breast cancer with a targeted therapy in the first-line setting,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This recommendation is
“We are thrilled about this second collaboration with Genentech, which expands our collaborative efforts in applying induced proximity concepts to include molecular glue types beyond targeted protein degraders,” said Niko Kley, Co-Founder and CEO of Orionis Biosciences. “The expansion of our existing strategic alliance underlines a strong alignment in vision
“Dosing the first patient in the TNG456 Phase 1/2 trial marks a significant step for us and for patients with MTAP-deleted GBM,” said Adam Crystal, M.D., Ph.D., President, Research and Development of Tango Therapeutics. “People with GBM currently have few treatment options and a five-year survival rate below 10%. 45%
“The ASCENT-03 outcome represents the first clinically meaningful advance for this patient population in over 20 years versus chemotherapy,” said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. “By addressing this aggressive and difficult to treat disease earlier, we can potentially improve treatment options for the high unmet need
